Metraipolis › archive › dc_5ade7fe7da35

Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment — Europe PMC PMID:41425703

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41425703
DOI
10.32604/or.2025.067824
License (as archived)
solo-consultazione
Archived
2026-11-08T05:09:06.287Z
SHA-256 of the archived text
d4599791083d8806a2601ee5e6e3c2e50a2ed87e6799d5e942822b6088aa6b33
Stable URL of this page
https://metraipolis.com/documento/dc_5ade7fe7da35

How to cite

Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment — Europe PMC PMID:41425703 — Europe PMC (en), https://europepmc.org/article/MED/41425703 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5ade7fe7da35 (Metraipolis archive dc_5ade7fe7da35, sha256 d4599791083d8806a2601ee5e6e3c2e50a2ed87e6799d5e942822b6088aa6b33)
BibTeX
@misc{dc5ade7fe7da35,
  title = {Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment — Europe PMC PMID:41425703},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41425703},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5ade7fe7da35; sha256 d4599791083d8806a2601ee5e6e3c2e50a2ed87e6799d5e942822b6088aa6b33},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41425703. Agents can read the archived copy with the MCP tool read_document.